Emerging antibody-based therapies for the treatment of acute myeloid leukemia

Linus Angenendt; Jan-Henrik Mikesch; Christoph Schliemann

doi:10.1016/j.ctrv.2022.102409

Emerging antibody-based therapies for the treatment of acute myeloid leukemia

Cancer Treat Rev. 2022 Jul:108:102409. doi: 10.1016/j.ctrv.2022.102409. Epub 2022 May 18.

Authors

Linus Angenendt¹, Jan-Henrik Mikesch², Christoph Schliemann²

Affiliations

¹ Department of Medicine A, University Hospital Münster, Münster, Germany; Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
² Department of Medicine A, University Hospital Münster, Münster, Germany.

PMID: 35605472
DOI: 10.1016/j.ctrv.2022.102409

Abstract

The development of antibody-based therapeutics for patients with acute myeloid leukemia (AML) has long been hampered due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells (HSPC). Nevertheless, the first antibody-drug conjugate has been approved for the treatment of AML in the recent years. In addition, multiple antibody-based therapeutics including antibody-drug conjugates, bispecific antibodies and immunocytokines are currently being developed in clinical trials with some of them demonstrating encouraging results alone and/or in combination with current standard therapies. In this review we discuss current concepts of antibody-based therapies and results from emerging antibody-based therapeutics for the treatment of AML.

Keywords: AML; Acute Myeloid Leukemia; Antibody; Antibody-drug conjugates; Bispecific antibodies; Immunocytokines.

Publication types

Review

MeSH terms

Antibodies, Bispecific* / therapeutic use
Humans
Immunoconjugates* / therapeutic use
Immunotherapy / methods
Leukemia, Myeloid, Acute* / drug therapy

Substances

Antibodies, Bispecific
Immunoconjugates